ClinicalTrials.gg

Program

fianlimab

Also written as “Fianlimab”, “Fianlimab+cemiplimab” and “FDC fianlimab+cemiplimab”.

Its studies are mostly in Melanoma · Carcinoma, Non-Small-Cell Lung · Squamous Cell Carcinoma of Head and Neck · Ependymoma · Neoplasms, led by Regeneron Pharmaceuticals.

Furthest: phase 3, since Apr 6, 202210 company-led studies, 9 open or runningNext primary completion: Jan 15, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Regeneron Pharmaceuticals109 open or runningphase 3since Apr 6, 2022Nov 18, 2016Jan 15, 2027phase 3 · NCT05608291

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 18, 2016First study: phase 1 study in NeoplasmsFirst studyNCT03005782 · 333 enrolled · United States, Australia, Ireland and more
  2. Apr 6, 2022Phase 3 study in MelanomaNCT05352672 · 1,546 enrolled · United States, Argentina, Australia and more
  3. Oct 14, 2022Phase 3 study in MelanomaNCT05608291 · 1,564 enrolled · United States, Argentina, Australia and more
  4. Mar 14, 20232 phase 3 studiesNCT05785767, NCT05800015
  5. Nov 29, 2023Phase 2 study in Resectable Non-small Cell Lung CancerNCT06161441 · 195 enrolled · United States, Australia, Chile and more
  6. Jan 30, 2024Phase 3 study in MelanomaNCT06246916 · 560 planned · United States, Canada
  7. Jan 6, 2025Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06769698 · 120 planned · United States, Australia, France and more
  8. Feb 24, 2025Phase 2 study in MelanomaNCT06848088 · 28 enrolled · United States, Ireland
  9. Apr 28, 2026Phase 2 study in GliomaNCT07567469 · 120 planned
  10. Nov 10, 2026Primary completion moved from 2029-10-10 to 2030-10-09Date moved laterphase 2 · +12 months · NCT06848088
  11. Nov 10, 2026Primary completion moved from 2026-07-27 to 2027-01-15Date moved laterphase 3 · +6 months · NCT05608291

Ahead

  1. Jan 15, 2027Primary completion: phase 3 study in MelanomaNCT05608291
  2. Mar 22, 2027Primary completion: phase 3 study in MelanomaNCT06246916
  3. Sep 28, 2027Primary completion: phase 3 study in Advanced Non-Small Cell Lung CancerNCT05785767
  4. Jun 4, 2028Primary completion: phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT06769698

TargetBeta

LAG3 →read by rule
“A monoclonal antibody directed against the inhibitory receptor lymphocyte activation gene-3 protein (LAG-3; LAG3; CD223), ”NCIt, by rule
“Lymphocyte activation gene 3 protein inhibitor”ChEMBL 37, by rule

Other programs on LAG3

ProgramCompanyFurthest phaseStudies
relatlimabruleBristol-Myers Squibbphase 419
Anti-PD-1/LAG-3 Bispecific Antibody AK129ruleAkesophase 24
TQB2252Sino Biopharmaceuticalphase 11

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07567469Glioma2Not yet recruitingAug 27, 2032120
NCT06848088Melanoma · United States, Ireland2Active, not recruitingOct 9, 203028
NCT06769698Squamous Cell Carcinoma of Head and Neck · United States, Australia, France and more2RecruitingJun 4, 2028120
NCT06246916Melanoma · United States, Canada3RecruitingMar 22, 2027560
NCT06161441Resectable Non-small Cell Lung Cancer · United States, Australia, Chile and more2Active, not recruitingAug 24, 2026195
NCT05800015Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more3Active, not recruitingJan 16, 2030160
NCT05785767Advanced Non-Small Cell Lung Cancer · United States, Australia, Canada and more3Active, not recruitingSep 28, 2027149
NCT05608291Melanoma · United States, Argentina, Australia and more3Active, not recruitingJan 15, 20271,564
NCT05352672Melanoma · United States, Argentina, Australia and more3Active, not recruitingMar 12, 20261,546
NCT03005782Neoplasms · United States, Australia, Ireland and more1CompletedApr 2, 2024333

How it is read

Names in the registry

  • “Fianlimab”, 3 entries
  • “fianlimab”, 3 entries
  • “Fianlimab+cemiplimab”, 1 entry
  • “FDC fianlimab+cemiplimab”, 1 entry
  • “Cemiplimab+Fianlimab Fixed Dose Combination (FDC)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.